UTHR

United Therapeutics Corporation (UTHR) | Rumor.io

United Therapeutics

UTHR

Attention (50-day avg)0%

Attention rank (50-day avg)#868

Bullish sentiment (50-day avg)52%

Price to earnings ratio17.4

Market capitalization20.8B

Earnings per share27.9

Dividend yield (TTM)—

Revenue (annual)3.2B

Net income (annual)1.3B

Social

What share of all stock conversation is about UTHR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0.01% +0.01	0% +0	0% 0

Aug 17

United Therapeutics Corporation has announced the full enrollment of the TETON-PPF study, which will evaluate inhaled treprostinil for the treatment of progressive pulmonary fibrosis.
The study's success could expand the potential market for Tyvaso, a treatment for idiopathic pulmonary fibrosis, to a larger patient population with progressive pulmonary fibrosis.
The company's CEO, M. Rothblatt, recently sold $4.7 million worth of shares, sparking insider sell concerns.

Generated by AI

Sentiment

Of the messages about UTHR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	5.81% -54.19	37.31% -22.1	64.33% -14.27
Bearish	—	94.19% +54.19	62.69% +22.1	35.67% +14.27

Bullish· Mar 30

$UTHR is primed for continuation with bulls in control, as buyers dominate the tape and the stock could keep running.
United Therapeutics' TETON-1 study meets primary endpoint for lung disease treatment, demonstrating improvement in absolute forced vital capacity and reducing the risk of clinical worsening.
$UTHR is expected to reach $1,000 stock soon, with a price target raised to $660 from $575 at TD Cowen, driven by a label expansion for Tyvaso and a sNDA submission planned for late summer.

Bearish· Apr 3

United Therapeutics' ($UTHR) shares fell due to regulatory delays for its Remosynch Implantable Pump, pushing back its product launch.
Insider selling contributed to the decline in United Therapeutics' ($UTHR) shares, with the company's stock trading down 8.4% on the news.
Credit Suisse reiterated a bearish stance on United Therapeutics ($UTHR), maintaining an "Underperform" rating despite some fundamental support.

Generated by AI

Topics

Of the messages about UTHR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	29.27%	52.94%	23.16%
Analysts	0%	70.73%	43.14%	27.07%
Earnings	0%	0%	0.98%	11.76%
Technical Analysis	0%	0%	2.94%	2.97%
Controversies	0%	0%	0%	12.27%
Macro	0%	0%	0%	22.77%

Earnings· May 3

United Therapeutics Corporation (UTHR) reported Q1 2023 earnings of $4.86 per share, beating estimates by $0.36.
Revenue for the quarter was $506.9M, missing estimates by $7.47M.
The company reported positive Q1 2023 financial results with revenue growth and strong product performance.

Analysts· Dec 23

United Therapeutics Corporation has been upgraded to "Buy" or "Outperform" by several analysts, including Ladenburg Thalmann, BMO Capital Markets, and Cowen and Company.
Price targets for the company have been raised, with Ladenburg Thalmann setting a target of $138 and BMO Capital Markets setting a target of $120.
Analysts have expressed positive sentiment towards the company, with some upgrades being seen as a sign of a "biotech blue sky" despite one upgrade being downgraded by another.

Announcements· Mar 9

United Therapeutics Corporation (UTHR) announced a $2 billion stock repurchase authorization and entered into a $1.5 billion accelerated share repurchase program.
The company will make an upfront payment of $1.5 billion to Citibank and receive an initial delivery of shares representing approximately 70% of the total shares anticipated to be repurchased under the uncollared ASR agreement.
The $2 billion stock repurchase program is expected to conclude by March 2027, with up to $500 million remaining available for additional buybacks at the company's discretion.

Technical Analysis· Oct 25

$UTHR broke down from VWAP after a dir established, with movement not being the smoothest of the day.
$UTHR had a nice follow-through after a rangy/blocky open, breaking out from a LOD with a deathstick.
$UTHR broke lows and bounced to almost-VWAP, with a slow burn through ~127.5 off VWAP 2 after a LOD break out gate.

Generated by AI

Community

Of the messages about UTHR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	27.17%	45.99%	75.23%
Newcomers	0%	72.83%	54.01%	24.77%

Regulars· Aug 5

United Therapeutics' Tyvaso DPI sales have seen a 4% YoY increase, contrary to the overall decline in Tyvaso sales.
The analysts' consensus for Tyvaso sales in Q2 was $484m, but the actual sales were $453m, a 6% miss.
United Therapeutics' management highlighted record Tyvaso DPI referrals, starts, commercial patients, and total patients in the recent call, suggesting a shift in focus towards the DPI version.

Newcomers· Mar 30

Newcomers are excited about the positive Phase 3 data for United Therapeutics' Tyvaso in IPF, with one user noting the drug's 7-year orphan protection in IPF could be overcome by a demonstration of superiority on efficacy or tolerability.
The TETON-1 study's primary endpoint was met with a significant 130.1 mL FVC improvement over placebo, and one user is questioning why this result might be underestimated.
United Therapeutics' stock has surged over 13% to reach a new 52-week high of $607.89, with some users speculating about the stock's potential to reach analyst targets of $700+ and others analyzing the company's financials and technical analysis.

Generated by AI

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will

17h agoBenzinga

United Therapeutics (UTHR): Goldman Says Sell As The Base Business Shrinks, But 2027 Holds Real Catalysts

Goldman Sachs analyst Andrea Newkirk initiated coverage of United Therapeutics Corporation (NASDAQ:UTHR) on September 24, 2026, with a Sell rating and a $321 price target. The firm argues that shares trade above their historical valuation range while the core franchise shrinks, and that the market underestimates how hard the idiopathic pulmonary fibrosis (IPF) launch will […]

1d agoYahoo Finance

What United Therapeutics (UTHR)'s Goldman Sell Call Amid Bold Pipeline And Buyback Means For Shareholders

Earlier this week, Goldman Sachs initiated coverage of United Therapeutics with a Sell rating, even as the company pursues an ambitious pipeline of 14 potential launches, including nebulized Tyvaso for idiopathic pulmonary fibrosis and once-daily oral ralinepag, alongside a US$2.00 billion share repurchase authorization. At the same time, United Therapeutics is pushing ahead with long-horizon xenotransplantation efforts, including a xenokidney registration trial that management aims to...

2d agoYahoo Finance

United Therapeutics: The Market Sees The Erosion, Not The Refill - Buy (NASDAQ:UTHR)

United Therapeutics' declines are real but they sit in ~32% of the business, tax-normalized earnings power is $1.05 billion. See why UTHR stock is a Buy now.

2d agoSeeking Alpha

United Therapeutics (UTHR) Falls On Goldman Sell Call, Is It Still 29% Undervalued?

United Therapeutics (UTHR) moved into focus after Goldman Sachs started coverage with a Sell rating, sending the stock down 4%, a meaningful single session move for a relatively steady biotech stock. Goldman’s call lands after a choppy stretch for United Therapeutics, with the share price down 7.76% over 30 days and 12.75% over 90 days, even though the 1-year total shareholder return of 9.89% and 3-year total shareholder return of 110.50% point to longer term momentum that appears...

2d agoYahoo Finance

United Therapeutics chairperson & CEO sells $4.7m in stock

3d agoInvesting.com

Also Discussed

Investors talking about UTHR also mention

#	Name	Attention
1	Liquidia CorporationLQDA	0.01%0
2	MannKind CorporationMNKD	0.02%+0.01
3	Insmed IncorporatedINSM	0%new
4	Ligand Pharmaceuticals IncorporatedLGND	0%0
5	Sanofi ADRSNY	0%-0.01
6	Amgen Inc.AMGN	0.01%+0
7	GSK plc ADRGSK	0%0
8	Leverage Shares 2X Long RTX Daily ETFRTXG	0%0
9	Myriad Genetics Inc.MYGN	0%0
10	Adicet Bio, Inc. Common StockACET	0%-0.01

United Therapeutics Corporation

Healthcare
Drug Manufacturers - Specialty & Generic

United Therapeutics Corporation is a biotechnology company specializing in therapies for pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease, and other serious conditions. Founded in 1996 and headquartered in Silver Spring, Maryland, the company operates as a public benefit corporation focused on developing innovative treatments and technologies. Its FDA-approved therapeutic portfolio includes Tyvaso (treprostinil), available in both inhalation powder and nebulized formulations; Remodulin Injection; Orenitram Extended-Release Tablets; Adcirca (tadalafil); and Unituxin for treating PAH and related conditions. Beyond traditional pharmaceuticals, United Therapeutics pursues transformational initiatives through its subsidiary Lung Biotechnology PBC to address the critical shortage of transplantable organs through xenotransplantation and bioengineering technologies. The company maintains a robust commercial presence, distributing products through healthcare provider networks and partnerships. Its pipeline includes clinical programs exploring new therapeutic indications, delivery mechanisms, and organ manufacturing solutions. United Therapeutics serves patients, healthcare providers, and research institutions globally, combining steady commercial performance with visionary medical innovation.

Website

Location

1000 Spring Street

Silver Spring, MD, 20910

United States

Social

What share of all stock conversation is about UTHR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0.01% +0.01	0% +0	0% 0

Aug 17

United Therapeutics Corporation has announced the full enrollment of the TETON-PPF study, which will evaluate inhaled treprostinil for the treatment of progressive pulmonary fibrosis.
The study's success could expand the potential market for Tyvaso, a treatment for idiopathic pulmonary fibrosis, to a larger patient population with progressive pulmonary fibrosis.
The company's CEO, M. Rothblatt, recently sold $4.7 million worth of shares, sparking insider sell concerns.

Generated by AI

Sentiment

Of the messages about UTHR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	5.81% -54.19	37.31% -22.1	64.33% -14.27
Bearish	—	94.19% +54.19	62.69% +22.1	35.67% +14.27

Bullish· Mar 30

$UTHR is primed for continuation with bulls in control, as buyers dominate the tape and the stock could keep running.
United Therapeutics' TETON-1 study meets primary endpoint for lung disease treatment, demonstrating improvement in absolute forced vital capacity and reducing the risk of clinical worsening.
$UTHR is expected to reach $1,000 stock soon, with a price target raised to $660 from $575 at TD Cowen, driven by a label expansion for Tyvaso and a sNDA submission planned for late summer.

Bearish· Apr 3

United Therapeutics' ($UTHR) shares fell due to regulatory delays for its Remosynch Implantable Pump, pushing back its product launch.
Insider selling contributed to the decline in United Therapeutics' ($UTHR) shares, with the company's stock trading down 8.4% on the news.
Credit Suisse reiterated a bearish stance on United Therapeutics ($UTHR), maintaining an "Underperform" rating despite some fundamental support.

Generated by AI

Topics

Of the messages about UTHR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	29.27%	52.94%	23.16%
Analysts	0%	70.73%	43.14%	27.07%
Earnings	0%	0%	0.98%	11.76%
Technical Analysis	0%	0%	2.94%	2.97%
Controversies	0%	0%	0%	12.27%
Macro	0%	0%	0%	22.77%

Earnings· May 3

United Therapeutics Corporation (UTHR) reported Q1 2023 earnings of $4.86 per share, beating estimates by $0.36.
Revenue for the quarter was $506.9M, missing estimates by $7.47M.
The company reported positive Q1 2023 financial results with revenue growth and strong product performance.

Analysts· Dec 23

United Therapeutics Corporation has been upgraded to "Buy" or "Outperform" by several analysts, including Ladenburg Thalmann, BMO Capital Markets, and Cowen and Company.
Price targets for the company have been raised, with Ladenburg Thalmann setting a target of $138 and BMO Capital Markets setting a target of $120.
Analysts have expressed positive sentiment towards the company, with some upgrades being seen as a sign of a "biotech blue sky" despite one upgrade being downgraded by another.

Announcements· Mar 9

United Therapeutics Corporation (UTHR) announced a $2 billion stock repurchase authorization and entered into a $1.5 billion accelerated share repurchase program.
The company will make an upfront payment of $1.5 billion to Citibank and receive an initial delivery of shares representing approximately 70% of the total shares anticipated to be repurchased under the uncollared ASR agreement.
The $2 billion stock repurchase program is expected to conclude by March 2027, with up to $500 million remaining available for additional buybacks at the company's discretion.

Technical Analysis· Oct 25

$UTHR broke down from VWAP after a dir established, with movement not being the smoothest of the day.
$UTHR had a nice follow-through after a rangy/blocky open, breaking out from a LOD with a deathstick.
$UTHR broke lows and bounced to almost-VWAP, with a slow burn through ~127.5 off VWAP 2 after a LOD break out gate.

Generated by AI

Community

Of the messages about UTHR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	27.17%	45.99%	75.23%
Newcomers	0%	72.83%	54.01%	24.77%

Regulars· Aug 5

United Therapeutics' Tyvaso DPI sales have seen a 4% YoY increase, contrary to the overall decline in Tyvaso sales.
The analysts' consensus for Tyvaso sales in Q2 was $484m, but the actual sales were $453m, a 6% miss.
United Therapeutics' management highlighted record Tyvaso DPI referrals, starts, commercial patients, and total patients in the recent call, suggesting a shift in focus towards the DPI version.

Newcomers· Mar 30

Newcomers are excited about the positive Phase 3 data for United Therapeutics' Tyvaso in IPF, with one user noting the drug's 7-year orphan protection in IPF could be overcome by a demonstration of superiority on efficacy or tolerability.
The TETON-1 study's primary endpoint was met with a significant 130.1 mL FVC improvement over placebo, and one user is questioning why this result might be underestimated.
United Therapeutics' stock has surged over 13% to reach a new 52-week high of $607.89, with some users speculating about the stock's potential to reach analyst targets of $700+ and others analyzing the company's financials and technical analysis.

Generated by AI

United Therapeutics

Social

Aug 17

Bullish· Mar 30

Bearish· Apr 3

Earnings· May 3

Analysts· Dec 23

Announcements· Mar 9

Technical Analysis· Oct 25

Regulars· Aug 5

Newcomers· Mar 30

10 Health Care Stocks Whale Activity In Today’s Session - United Therapeutics (NASDAQ:UTHR), Iovance Biot

United Therapeutics (UTHR): Goldman Says Sell As The Base Business Shrinks, But 2027 Holds Real Catalysts

What United Therapeutics (UTHR)'s Goldman Sell Call Amid Bold Pipeline And Buyback Means For Shareholders

United Therapeutics: The Market Sees The Erosion, Not The Refill - Buy (NASDAQ:UTHR)

United Therapeutics (UTHR) Falls On Goldman Sell Call, Is It Still 29% Undervalued?

United Therapeutics chairperson & CEO sells $4.7m in stock

Also Discussed

United Therapeutics Corporation

Company Information

Location

10 Health Care Stocks Whale Activity In Today’s Session - United Therapeutics (NASDAQ:UTHR), Iovance Biot

United Therapeutics (UTHR): Goldman Says Sell As The Base Business Shrinks, But 2027 Holds Real Catalysts

What United Therapeutics (UTHR)'s Goldman Sell Call Amid Bold Pipeline And Buyback Means For Shareholders

United Therapeutics: The Market Sees The Erosion, Not The Refill - Buy (NASDAQ:UTHR)

United Therapeutics (UTHR) Falls On Goldman Sell Call, Is It Still 29% Undervalued?

United Therapeutics chairperson & CEO sells $4.7m in stock

Also Discussed

Social

Aug 17

Bullish· Mar 30

Bearish· Apr 3

Earnings· May 3

Analysts· Dec 23

Announcements· Mar 9

Technical Analysis· Oct 25

Regulars· Aug 5

Newcomers· Mar 30